The measurement of circulating nucleic acids has transformed the management of chronic viral infections such as HIV. The development of analogous markers for individuals with cancer could similarly enhance the management of their disease. DNA containing somatic mutations is highly tumor specific and thus, in theory, can provide optimum markers. However, the number of circulating mutant gene fragments is small compared to the number of normal circulating DNA fragments, making it difficult to detect and quantify them with the sensitivity required for meaningful clinical use. In this study, we applied a highly sensitive approach to quantify circulating tumor DNA (ctDNA) in 162 plasma samples from 18 subjects undergoing multimodality therapy for colorectal cancer. We found that ctDNA measurements could be used to reliably monitor tumor dynamics in subjects with cancer who were undergoing surgery or chemotherapy. We suggest that this personalized genetic approach could be generally applied to individuals with other types of cancer (pages 914–915).
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Journal of Biomedical Science Open Access 09 August 2023
Journal of Experimental & Clinical Cancer Research Open Access 04 August 2023
Genome Medicine Open Access 03 May 2023
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Wood, L.D. et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108–1113 (2007).
Nagrath, S. et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450, 1235–1239 (2007).
Cristofanilli, M. et al. Circulating tumor cells, disease progression and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781–791 (2004).
Sidransky, D. Emerging molecular markers of cancer. Nat. Rev. Cancer 2, 210–219 (2002).
Goebel, G., Zitt, M., Zitt, M. & Muller, H.M. Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias. Dis. Markers 21, 105–120 (2005).
Fleischhacker, M. & Schmidt, B. Circulating nucleic acids (CNAs) and cancer—a survey. Biochim. Biophys. Acta 1775, 181–232 (2007).
Gormally, E., Caboux, E., Vineis, P. & Hainaut, P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat. Res. 635, 105–117 (2007).
Diehl, F. et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl. Acad. Sci. USA 102, 16368–16373 (2005).
Dressman, D., Yan, H., Traverso, G., Kinzler, K.W. & Vogelstein, B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc. Natl. Acad. Sci. USA 100, 8817–8822 (2003).
Goldstein, M.J. & Mitchell, E.P. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 23, 338–351 (2005).
Li, H., Fan, X. & Houghton, J. Tumor microenvironment: the role of the tumor stroma in cancer. J. Cell. Biochem. 101, 805–815 (2007).
Hacia, J.G. & Collins, F.S. Mutational analysis using oligonucleotide microarrays. J. Med. Genet. 36, 730–736 (1999).
Shendure, J., Mitra, R.D., Varma, C. & Church, G.M. Advanced sequencing technologies: methods and goals. Nat. Rev. Genet. 5, 335–344 (2004).
Rago, C. et al. Serial Assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res. 67, 9364–9370 (2007).
Diehl, F. et al. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat. Methods 3, 551–559 (2006).
Li, M., Diehl, F., Dressman, D., Vogelstein, B. & Kinzler, K.W. BEAMing up for detection and quantification of rare sequence variants. Nat. Methods 3, 95–97 (2006).
We thank G.Traverso for useful discussions; D. Heslop, C. Vaughn and D. Edelstein for their help with plasma collection; and L. Fayad for help with the interpretation of imaging studies. This work was supported by the Virginia and D.K. Ludwig Fund for Cancer Research, the Miracle Foundation, the US National Colorectal Cancer Research Alliance and US National Institutes of Health grants CA43460, CA57345, CA62924 and CA129825.
Under agreements between the Johns Hopkins University and Exact Sciences, Genzyme Molecular Oncology and Beckman Instruments, K.W.K. and B.V. are entitled to a share of the royalties received by the University on sales of products related to certain of the genes described in this paper. The University and these authors also own stock in Exact Sciences and Genzyme, which is subject to certain restrictions under University policy. K.W.K., B.V., F.D., K.S., M.L. and L.A.D., Jr. are listed as inventors on patent applications filed by the University that are relevant to the results described in this paper. The terms of these arrangements are being managed by the University in accordance with its conflict of interest policies.
About this article
Cite this article
Diehl, F., Schmidt, K., Choti, M. et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 14, 985–990 (2008). https://doi.org/10.1038/nm.1789
This article is cited by
Molecular Cancer (2023)
DREAMS: deep read-level error model for sequencing data applied to low-frequency variant calling and circulating tumor DNA detection
Genome Biology (2023)
Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application
Molecular Cancer (2023)
Genome Medicine (2023)
Journal of Experimental & Clinical Cancer Research (2023)